TL;DR
- •Legitimate ketamine therapy providers conduct a full psychiatric history, screen for cardiovascular and substance-use risks, check the prescription monitoring program (PMP), and maintain ongoing clinical follow-up — not just mail you medication.
- •Telehealth ketamine and clinic-based ketamine both have legitimate forms. Telehealth is more accessible and lower-cost; clinic-based is more appropriate for higher-acuity patients or those needing in-person supervision.
- •MD/DO vs nurse practitioner: both can prescribe ketamine in appropriate scope-of-practice arrangements. What matters is the clinical depth — board certification in psychiatry, supervision structure, escalation pathways for complications.
- •Red flags: no medical history intake before prescription, no PMP check, no follow-up after dosing, "mail-only" model without consultation, no escalation pathway for adverse events, no review of other medications.
- •Green flags: board-certified physicians (psychiatry, internal medicine, or family medicine with addiction/mental-health experience), telehealth + licensed pharmacy partner, real consultations (not just questionnaires), structured follow-up cadence, response monitoring (PHQ-9/GAD-7).
- •Ketamine vs other modalities (psilocybin, TMS, ECT): ketamine is currently the most accessible rapid-action option; psilocybin therapy is approved only in specific research and Oregon/Colorado contexts; TMS and ECT have well-established evidence and different risk profiles. The "right" modality depends on severity, treatment history, and access.
Step by step
- 1
Pre-screening — does the provider take medical history?
A legitimate provider conducts a thorough medical and psychiatric history before prescribing — current medications, prior treatments, psychiatric history, cardiovascular history, substance-use history, allergies, current life context. If a provider prescribes ketamine after a 5-minute questionnaire, that's a red flag.
- 2
Screening — do they check cardiovascular and PMP?
Ketamine raises blood pressure transiently — uncontrolled hypertension is a contraindication. Legitimate providers ask about blood pressure, recent measurements, cardiovascular conditions. They also check the prescription monitoring program (PMP) for patterns suggesting opioid or benzodiazepine misuse. Skipping these steps is a safety red flag.
- 3
Initial consultation — is there real clinical contact?
A legitimate consultation includes a video or in-person visit with the prescribing clinician — discussing your symptoms, treatment goals, prior treatments, current life context, and the protocol details. Length matters: 30-60 minutes for an initial consultation is typical; 10-15 minutes for "intake" alone is light.
- 4
Dosing supervision — are sessions supervised?
At-home telehealth: physician video check-in before dosing, ongoing availability during the session, post-session integration call. In-clinic: direct in-person supervision. "Send the medication, you handle it" without supervision is not a legitimate ketamine therapy model — it's mail-order ketamine.
- 5
Follow-up — is response tracked?
Legitimate providers use validated outcome measures (PHQ-9 for depression, GAD-7 for anxiety, PCL-5 for PTSD) and track response across the treatment course. They adjust protocol based on response, not on a fixed timeline. Absence of outcome tracking is a red flag — without measurement, there's no basis for protocol adjustment.
- 6
Escalation — what happens if something goes wrong?
A legitimate provider has a clear pathway for adverse events: someone you can reach during a session, prescribing-physician access for medication concerns, referral options for issues beyond their scope. "Email us and we'll respond in 2 days" isn't a legitimate escalation pathway for an active session.
What this actually feels like
Choosing a provider is partly a feeling — the legitimate clinics and telehealth services feel like medical care. There's an intake, a real consultation, follow-up appointments, response tracking, the sense that someone is genuinely paying attention to your specific situation. The shadier operations feel like e-commerce — fast checkout, minimal questions, "your meds will arrive in 3-5 days." If the experience feels more like buying a product than receiving medical care, trust that signal. Ketamine therapy in 2026 has matured into a mainstream treatment with established standards; you don't need to settle for an operation that doesn't feel clinically serious.
Timeline
Evaluating a provider: 1-2 hours of research before signing up. Reading their website, checking physician credentials (state licensure boards are public), reading patient reviews from multiple sources (not just their own testimonials). Initial consultation: 30-60 minutes. From initial consultation to first session: 1-2 weeks typically (allows for prescription, pharmacy fulfillment, and scheduling). If a provider can go from "first contact" to "medication in your hand" in 48 hours, that speed itself is a red flag — meaningful medical evaluation takes longer.
Common concerns, addressed
“I see many ketamine companies advertising — are they all legitimate?”
No. The ketamine telehealth market has grown rapidly and quality varies widely. Some operations cut every clinical corner; some run rigorous protocols comparable to or better than in-person clinics. Evaluation criteria matter more than advertising volume. Look for: physician credentials, screening rigor, supervision, follow-up structure, outcome tracking.
“Is telehealth ketamine as effective as in-clinic ketamine?”
For appropriate patients (those who pass screening, can arrange a supportive home environment, don't need acute in-person supervision), published evidence supports telehealth ketamine producing comparable outcomes to in-clinic protocols. For higher-acuity patients (active suicidality, complex medical conditions, severe substance use), in-clinic care may be more appropriate. Mathai 2024 documented favorable real-world outcomes for at-home telehealth.
“Should I see an MD/DO rather than a nurse practitioner?”
Either can be appropriate. The credentials are less important than the structure: board certification in psychiatry (or relevant specialty), supervision arrangement (NPs working under physician supervision is standard), depth of psychiatric training, escalation pathways. A board-certified MD/DO psychiatrist running solo isn't automatically better than an NP working in a structured team led by a board-certified psychiatrist.
“What about psilocybin or other psychedelics?”
Different modalities, different access. Psilocybin therapy in the US is currently approved only in Oregon and Colorado state-licensed programs, plus research settings; the Carhart-Harris 2021 trial documented promising results comparing psilocybin to escitalopram for depression. For most US patients today, ketamine is the accessible rapid-action option. As regulatory landscape changes, other psychedelics may become more available; current evidence-based mainstream options remain ketamine, TMS, ECT, and (for severe cases) IV racemic ketamine in clinic.
“Is mail-only ketamine ever legitimate?”
Mail-only delivery is a logistics question, not a quality question — many legitimate providers ship medication after thorough clinical evaluation. What's NOT legitimate: prescription without consultation, no follow-up, no supervision, no clinical contact beyond the questionnaire. Distinguish between "telehealth + mail-order pharmacy" (legitimate model) and "buy ketamine online with no clinical care" (not legitimate).
“How do I check if a provider is properly licensed?”
State medical board websites list licensed physicians publicly. State board of nursing lists licensed NPs. Many state pharmacy boards list licensed pharmacies. Search by name. Disciplinary actions and license restrictions are publicly visible. A legitimate provider has nothing to hide on these databases.
Who this fits best
Telehealth ketamine providers (like Tovani) fit patients who: have controlled blood pressure, can arrange a supportive home environment, want lower-cost and more accessible treatment, value flexibility in scheduling, and don't need acute in-person psychiatric supervision. In-clinic IV ketamine fits patients with: more complex medical conditions, active acute suicidality, history of pathological dissociation, or those who simply prefer in-person care. Higher-acuity patients (active psychosis, severe substance use, severe untreated bipolar) need different settings entirely — not because ketamine is wrong but because the structure of care needs to be more intensive.
Ready to start?
Tovani offers board-certified telehealth ketamine therapy for treatment-resistant depression, anxiety, PTSD, and chronic pain. Available in Florida and New Jersey.
Check eligibility5-minute screening · Reviewed by a board-certified physician · FL & NJ
Frequently asked
How do I know if a ketamine company is legitimate?
Check for: licensed physician prescribers (verify via state medical board), thorough intake including medical and psychiatric history, real consultations (not just questionnaires), PMP check, structured follow-up with response tracking, clear escalation pathway. If any of these are absent, that's a red flag.
Is at-home ketamine safe?
For appropriate patients (screened for cardiovascular and substance-use risks, can arrange supportive home environment) with supervised telehealth protocols, yes. Mathai 2024 documented favorable real-world safety in at-home telehealth settings. Inappropriate patients (uncontrolled hypertension, active substance use, acute suicidality without monitoring) need different settings.
What's the difference between sublingual and IV ketamine providers?
Sublingual ketamine is administered as a lozenge or troche, typically in at-home telehealth or clinic settings. IV ketamine is administered as an intravenous infusion in clinic. IV produces faster onset and is sometimes used for patients who don't respond to sublingual. Both modalities are evidence-based; the choice depends on response, access, cost, and clinical fit.
Do I need a referral from my primary doctor or psychiatrist?
Usually not — most ketamine providers conduct their own clinical evaluation. But coordination with your existing care team matters: your primary doctor and current psychiatrist should know you're starting ketamine, and you should share their information with the ketamine provider. Treatment in isolation is suboptimal.
What questions should I ask before signing up?
Who is the prescribing physician (and what's their board certification)? What's the screening process? How is the session supervised? What outcome measures are tracked? How often will I have follow-up appointments? What's the escalation pathway if I have a complication? What happens if I don't respond? If the provider can't answer these clearly, look elsewhere.
References
- Sanacora G et al. 2017, JAMA Psychiatry. APA consensus on ketamine in mood disorders — establishes clinical standards for screening, supervision, dosing, and follow-up in ketamine treatment programs. PMID 28249076
- Mathai DS et al. 2024 — at-home telehealth ketamine for depression. Longitudinal study of at-home telehealth ketamine treatment — documents real-world outcomes in supervised telehealth settings comparable to clinic-based protocols. PMID 38810787
- CarhartHarris RL et al. 2021, New England Journal of Medicine. Trial of psilocybin versus escitalopram for depression — provides context for considering psilocybin-assisted therapy as an alternative modality in the broader treatment landscape. PMID 33852780
- Jelen LA et al. 2024 — clinical psychiatry practice guidelines for ketamine. Clinical guidelines for ketamine use — outlines screening, dosing, supervision, and follow-up standards relevant for evaluating provider quality. PMID 38725375